VBWG
Slides

Cardiovascular considerations in treating erectile dysfunction

• Impact of vascular biology in treatment of cardiovascular disease

This slide presentation covers basic science and clinical advances in treatment of erectile dysfunction, with emphasis on the cardiovascular patient. The material is presented in five sections:
  • Section I: Clinical and epidemiological correlates of erectile dysfunction and cardiovascular disease
  • Section II: Basic science update: PDE5 inhibition and endothelial dysfunction
  • Section III: Efficacy and safety of PDE5 inhibition
  • Section IV: Novel therapies for the treatment of erectile dysfunction
  • Section V: Erectile dysfunction: The patients you see

These timely materials contain information from recent studies that address educational objectives with the following goals:

  • Understand the importance of erectile dysfunction as an indicator of more serious underlying or associated medical problems that increase with age
  • Explain new basic science concepts that suggest a commonality of underlying disease pathways for cardiovascular disease and erectile dysfucntion
  • Explain the role of phosphodiesterase type 5 (PDE5) inhibition for improving endothelial function and thereby help to achieve a long-term beneficial impact on progression of atherosclerosis and its adverse manifestations
  • Update the audience on clinical trial evidence establishing the safety of PDE5 inhibition and the contraindications to its effective use
  • Suggest simplified clinical algorithms for risk stratification and patient management of concomitant cardiovascular disease and erectile dysfunction



    corerefs.pdf (0.0MB)corerefs.pdf (0.0MB)

    Section I: Clinical and epidemiological correlates of erectile dysfunction and cardiovascular disease

    Download PDE5S001.ppt (8 slides - 1.3MB)

    Section I: Clinical and epidemiological correlates of erectile dysfunction and cardiovascular disease Epidemiology of erectile dysfunction Age-related comorbidities in males Classification of erectile dysfunction Risk factor conditions shared by both erectile dysfunction and cardiovascular disease Association of erectile dysfunction and CV risk Erectile dysfunction in hypertensive men Degree of ED related to extent of CAD

    Section: II: Basic science update: PDE5 inhibition and endothelial dysfunction

    Download PDE5S002.ppt (7 slides - 1.3MB)

    Section: II: Basic science update: PDE5 inhibition and endothelial dysfunction Evolution of atherosclerotic plaque Erectile dysfunction = endothelial dysfunction Role of PDE5 in penile erection Anatomy of penile erection Hemodynamics of penile erection Strategies for improving NO bioavailability and endothelial function

    Section III: Efficacy and safety of PDE5 inhibition

    Download PDE5S003.ppt (32 slides - 6.0MB)

    Section III: Efficacy and safety of PDE5 inhibition Tissue distribution of phosphodiesterases PDE5 inhibition potentiates NO bioavailability Effects of sildenafil on penile erection in men with ischemic heart disease Effects of sildenafil on penile erection in men with ischemic heart disease (cont’d) Effects of sildenafil on sexual function in men with ischemic heart disease PDE5 inhibition improves coronary artery endothelial function PDE5 inhibition increases and prolongs brachial artery flow-mediated vasodilation PDE5 inhibition reduces GP IIb/IIIa-receptor activation PDE5 inhibition: Dose-dependent effect on endothelial function in patients with heart failure PDE5 inhibition: Effect on blood pressure in healthy middle-aged men PDE5 inhibition improves arterial stiffness in hypertensive patients PDE5 inhibition and mitochondrial KATP channel opening: Mechanism of cardioprotection Neutral effect of PDE5 inhibition on exercise-test hemodynamics Neutral effect of PDE5 inhibition on exercise echocardiography Evaluation of PDE5 inhibition in 14 men with severe CAD: Baseline characteristics PDE5 inhibition: No effect on coronary blood flow in men with severe CAD Effects of PDE5 inhibition on exercise-induced angina: Study design PDE5 inhibition: Effects on exercise parameters Effect of PDE5 inhibition on treadmill exercise Effect of PDE5 inhibition on treadmill exercise (cont'd) Safety profile of sildenafil in men with or without ischemic heart disease Safety profile of tadalafil in men with diabetes Sildenafil: Incidence of MI and all-cause mortality in clinical studies PDE5 inhibition improves hemodynamics in pulmonary arterial hypertension Comparative hemodynamic effects of PDE5 inhibition and nitrates Safety profile of sildenafil in treated and untreated hypertensive men PDE5 inhibition attenuates heart rate increase during exercise PDE5 inhibition improves hemodynamics and exercise tolerance in CHF PDE5 inhibition reduces pulmonary vascular resistance in children after heart surgery PDE5 inhibition: Improved vasodilation and gas exchange in lung fibrosis PDE5 inhibition promotes functional recovery after stroke in rats

    Section IV:  Novel therapies for the treatment of erectile dysfunction

    Download PDE5S004.ppt (7 slides - 1.2MB)

    Section IV:  Novel therapies for the treatment of erectile dysfunction Chemical structures of PDE5 inhibitors vs cGMP Selectivity of sildenafil for PDE1-6 Selectivity of sildenafil for PDE7-11 Cellular localization of PDE11 and the contribution of PDE11 inhibition to nerve-stimulated relaxation Pharmacokinetics of PDE5 inhibitors Pharmacokinetics of PDE5 inhibitors (cont'd)

    Section V: Erectile dysfunction: The patients you see

    Download PDE5S005.ppt (9 slides - 1.5MB)

    Section V: Erectile dysfunction: The patients you see Importance of vascular clues Energy requirements (METS) of selected physical activities Onset of MI following sexual activity Sexual activity and MI: Protective effect of regular exercise Levels of risk for a CV event triggered by sexual activity Levels of risk for a CV event triggered by sexual activity (cont'd) Levels of risk for a CV event triggered by sexual activity (cont'd) Suggested algorithm for management of erectile dysfunction in patients at risk for CV events

    Published by Medical Education Consultants, Inc. (MEDCON), on behalf of the University of Florida College of Medicine.

    The editorial content of this program does not necessarily reflect the views or recommendations of the University of Florida College of Medicine, Pfizer Inc, or the publisher. The reader is advised to consult the full prescribing information of each product prior to use.

    This program was prepared and produced by Medical Education Consultants Inc, Westport, Connecticut, on behalf of the University of Florida College of Medicine through an unrestricted educational grant provided by Pfizer Inc.

    ©2002 Medical Education Consultants, Inc. (MEDCON). All rights reserved.

    basicbiologycardiovascularconsiderationscoversDysfunctionemphasiserectilevascular

Related at vwbg.org

Core Curriculum

Impact of vascular biology in treatment of cardiovascular disease Section IV: Antithrombotic interventions in acute coronary syndromes

The VBWG Core Curriculum 2002 slide lecture program, Impact of vascular biology in treatment of cardiovascular disease, covers basic science and clinical advances in vascular biology in a spectrum of disorders.

Core Curriculum

Impact of vascular biology in treatment of cardiovascular disease Section III: Neurohormonal strategies in heart failure

The VBWG Core Curriculum 2002 slide lecture program, Impact of vascular biology in treatment of cardiovascular disease, covers basic science and clinical advances in vascular biology in a spectrum of disorders.

Core Curriculum

Impact of vascular biology in treatment of cardiovascular disease Section II: Lipid management

The VBWG Core Curriculum 2002 slide lecture program, Impact of vascular biology in treatment of cardiovascular disease, covers basic science and clinical advances in vascular biology in a spectrum of disorders.
More related